Education
- 2006 – 2009: PhD in Clinical Methodology, Università degli Studi di Milano
- 2001 – 2006: Residency Program in Internal Medicine, Università degli Studi di Milano
- 2000: Degree in Medicine, Università degli Studi di Milano
Academic Appointments
- 2025 – present: PhD Board, Personalized caRe and Innovation in Medicine and Engineering (PRIME), Humanitas University and Politecnico of Milan
- 2019 – 2022: Associate Professor of Internal Medicine, Humanitas University
- 2017 – 2019: Assistant Professor of Internal Medicine, Humanitas University
Awards and Honors
- 2025 – present: Vice Secretary General, European Association for the Study of the Liver
- 2022 – 2025: Scientific Committee, European Association for the Study of the Liver
- 2020 – 2023: Scientific Committee, Italian Association of Internal Medicine, Lombardy section
Her main research interests aim to clarifying the pathogenesis of autoimmune liver disease, in particular Primary Biliary Cholangitis (CBP). She described for the first time specific characteristics of epithelial cells in the bile duct, the target of the CBP immune attack, which would seem essential to explain the biliary specificity of CBP, the recurrence of disease after liver transplantation, and the therapeutic success of ursodesoxic acid.
She is a member of the International Study Group for PBC (PBC Global Group), of the International PSC Study Group and the International Autoimmune Hepatitis Network.
- EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. J Hepatol. 2025 Aug;83(2):453-501. doi: 10.1016/j.jhep.2025.03.017.
- Milardi G, Franceschini B, Camisaschi C, Puccio S, Costa G, Soldani C, Uva P, Cangelosi D, Carriero R, Lambroia L, Cammarota A, Lodetti-Zangrandi G, Malenica I, Erreni M, Montali I, Lottini T, Raggi C, Kunderfranco P, Polidoro MA, Aghemo A, Balsano R, Pressiani T, Piscuoglio S, Di Tommaso L, Torzilli G, Rimassa L, Lugli E, Cassani B, Lleo A. Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome.
- Colapietro F, Maisonneuve P, Lytvyak E, Beuers U, Verdonk RC, van der Meer AJ, van Hoek B, Kuiken SD, Brouwer JT, Muratori P, Aghemo A, Carella F, van den Berg AP, Zachou K, Dalekos GN, Di Zeo-Sánchez DE, Robles M, Andrade RJ, Montano-Loza AJ, van den Brand FF, Slooter CD, Macedo G, Liberal R, de Boer YS, Lleo A. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis. J Hepatol. 2024 Jan;80(1):53-61. doi: 10.1016/j.jhep.2023.09.010.
- Alvisi G, Termanini A, Soldani C, Portale F, Carriero R, Pilipow K, Costa G, Polidoro M, Franceschini B, Malenica I, Puccio S, Lise V, Galletti G, Zanon V, Colombo FS, De Simone G, Tufano M, Aghemo A, Di Tommaso L, Peano C, Cibella J, Iannacone M, Roychoudhuri R, Manzo T, Donadon M, Torzilli G, Kunderfranco P, Di Mitri D, Lugli E, Lleo A. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. J Hepatol 2022, Nov;77(5):1359-1372. doi: https://doi.org/10.1016/j.jhep.2022.05.043
- Lleo A, Wang G-Q, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet 2020 12;396(10266):1915-1926. doi: 10.1016/S0140-6736(20)31607-X.